Royal Bank of Canada’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Royal Bank of Canada’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-1,000	Closed	-$6K	–	6468
2013 Q3	$6K	Sell	1,000 -3,485	-78%	-$22.2K	﹤0.01%	5609
2013 Q2	$31K	Buy	+4,485	New	+$31.2K	﹤0.01%	4878

Other funds holding CADX

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Royal Bank of Canada's CADX Position: Q4 2013 in Review

Royal Bank of Canada sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q4 2013, closing a stake of 1,000 shares — an estimated $6K sold.

Royal Bank of Canada first reported a position in CADX in Q2 2013 and held it in 2 quarters. The position peaked at $31K in Q2 2013. 100 funds tracked by Wall St. Rank hold CADX as of Q4 2013.

Royal Bank of Canada reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q4 2013 after selling out during the quarter.
Royal Bank of Canada sold 1,000 CADENCE PHARMACEUTICALS, INC COM STK shares in Q4 2013, an estimated $6K.
Royal Bank of Canada first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 2 quarters.
Royal Bank of Canada's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $31K in Q2 2013.
100 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q4 2013.

Based on Royal Bank of Canada's 13F filing for Q4 2013, filed 14 Feb 2014.